Studying genes in hereditary angioedema
Part of Genetic & congenital, Immune system & allergy clinical trials.
This study looks at the genes that cause hereditary angioedema (HAE), a condition with sudden swelling in the hands, feet, face, or airways. By joining, you help doctors understand the disease better, which could lead to better care for you and others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of hereditary angioedema (HAE) due to C1 inhibitor deficiency, or you must be at least 22 years old with the deficiency but have never had swelling episodes.
- Your diagnosis must be confirmed by a genetic test or by low C1 inhibitor function (less than 50% on two tests) plus a family history.
- You cannot have a type of swelling that is caused by allergies (responds to antihistamines or steroids).
- You must be able to sign a consent form agreeing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study uses a smartphone app to track how hereditary angioedema affects your daily life over 8 weeks. It aims to better understand the real-world burden of the condition and may help improve care.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study is looking at how hereditary angioedema (a rare cause of severe swelling) is diagnosed and managed in Egypt. It is an observational study, meaning you won't receive any study medicine—just regular medical care while researchers collect information.
This study collects blood samples (and optional skin samples) from people with angioedema to learn more about the condition and find better ways to diagnose and treat it. If you join, you may help scientists understand angioedema better.
This trial tests a plasma-derived C1 esterase inhibitor to treat and prevent acute attacks in people with hereditary angioedema (HAE) types 1 or 2. It aims to see if the medicine can quickly relieve swelling episodes and reduce their frequency.
Hear when a new Hereditary Angioedema With C1 Esterase Inhibitor Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.